WO2010039861A3 - Dendrimer conjugates - Google Patents

Dendrimer conjugates Download PDF

Info

Publication number
WO2010039861A3
WO2010039861A3 PCT/US2009/059071 US2009059071W WO2010039861A3 WO 2010039861 A3 WO2010039861 A3 WO 2010039861A3 US 2009059071 W US2009059071 W US 2009059071W WO 2010039861 A3 WO2010039861 A3 WO 2010039861A3
Authority
WO
WIPO (PCT)
Prior art keywords
conjugates
present
therapy
diagnostic
dendrimer
Prior art date
Application number
PCT/US2009/059071
Other languages
French (fr)
Other versions
WO2010039861A2 (en
Inventor
James R. Baker, Jr.
Xue-Min Cheng
Abraham F.L. Van Der Spek
Baohua Mark Huang
Thommey P. Thomas
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of WO2010039861A2 publication Critical patent/WO2010039861A2/en
Publication of WO2010039861A3 publication Critical patent/WO2010039861A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
PCT/US2009/059071 2008-09-30 2009-09-30 Dendrimer conjugates WO2010039861A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10146108P 2008-09-30 2008-09-30
US61/101,461 2008-09-30

Publications (2)

Publication Number Publication Date
WO2010039861A2 WO2010039861A2 (en) 2010-04-08
WO2010039861A3 true WO2010039861A3 (en) 2010-08-19

Family

ID=42074189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/059071 WO2010039861A2 (en) 2008-09-30 2009-09-30 Dendrimer conjugates

Country Status (2)

Country Link
US (2) US8889635B2 (en)
WO (1) WO2010039861A2 (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8252834B2 (en) 2008-03-12 2012-08-28 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
US9017644B2 (en) * 2008-11-07 2015-04-28 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
WO2010075423A2 (en) * 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
US8968818B2 (en) * 2009-02-21 2015-03-03 Covidien Lp Medical devices having activated surfaces
MX2011012597A (en) 2009-05-27 2012-04-19 Selecta Biosciences Inc Nanocarriers possessing components with different rates of release.
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
US8912323B2 (en) 2009-10-30 2014-12-16 The Regents Of The University Of Michigan Multifunctional small molecules
CN107080839A (en) 2010-05-26 2017-08-22 西莱克塔生物科技公司 The synthesis nano-carrier vaccine of multivalence
US20120136416A1 (en) * 2010-11-19 2012-05-31 President And Fellows Of Harvard College Caged Neuropeptides: modulation and measurement of synapse and signaling activity; and methods for drug evaluation, pharmaceuticals preparation and treatment
WO2012092552A1 (en) * 2010-12-30 2012-07-05 Selecta Biosciences, Inc. Synthetic nanocarriers with reactive groups that release biologically active agents
CN103702687A (en) 2011-07-29 2014-04-02 西莱克塔生物科技公司 Synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte (CTL) immune responses
CA2843875C (en) 2011-08-12 2020-01-07 Ascendis Pharma A/S High-loading water-soluble carrier-linked prodrugs
CA2843503C (en) 2011-08-12 2020-12-22 Ulrich Hersel Polymeric hyperbranched carrier-linked prodrugs
US9889222B2 (en) 2011-11-09 2018-02-13 Kimberly-Clark Worldwide, Inc. Aqueous medium-sensitive coating compositions for triggered release of active ingredients and visual indication for wetness
US8791045B2 (en) 2011-11-09 2014-07-29 Kimberly-Clark Worldwide, Inc. Non-tacky wetness indicator composition for application on a polymeric substrate
WO2013085718A1 (en) 2011-12-08 2013-06-13 The Regents Of The University Of Michigan Multifunctional small molecules
US11213500B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9468599B2 (en) 2011-12-27 2016-10-18 Cmpd Licensing, Llc Composition and method for compounded therapy
US10813897B2 (en) 2011-12-27 2020-10-27 Cmpd Licensing, Llc Composition and method for compounded therapy
US11213501B2 (en) 2011-12-27 2022-01-04 Cmpd Licensing, Llc Composition and method for compounded therapy
US9962391B2 (en) 2011-12-27 2018-05-08 Cmpd Licensing, Llc Composition and method for compounded therapy
US9585826B2 (en) 2012-11-07 2017-03-07 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of active chemistry
US9050302B2 (en) 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9732113B2 (en) * 2013-03-13 2017-08-15 Agilent Technologies, Inc. Dendrimeric dye-containing oligonucleotide probes and methods of preparation and uses thereof
US9119780B2 (en) 2013-10-30 2015-09-01 Kimberly-Clark Worldwide, Inc. Triggerable compositions for two-stage, controlled release of proactive chemistry
US9192570B2 (en) 2013-12-20 2015-11-24 AntiOP, Inc. Intranasal naloxone compositions and methods of making and using same
CA2957721C (en) 2014-08-13 2021-04-13 The Johns Hopkins University Selective dendrimer delivery to brain tumors
CN114392360A (en) * 2014-08-13 2022-04-26 约翰霍普金斯大学 Dendrimer compositions and use in the treatment of neurological and CNS disorders
KR20180058737A (en) * 2015-10-07 2018-06-01 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 Trigger-activated metabolic precursor for cancer selective targeting and targeting
US11590241B2 (en) 2016-02-18 2023-02-28 Virginia Commonwealth University Nanoparticle conjugated synthetic opioid prodrugs and methods of their uses
WO2017216768A1 (en) 2016-06-16 2017-12-21 Association For The Advancement Of Tissue Engineering And Cell Based Technologies And Therapies - A4Tec Dendrimer-derived artificial antigen, methods and uses thereof
US10201553B1 (en) * 2016-07-18 2019-02-12 H Smart Inc. Composition of natural products for improved brain functioning
CN107137715B (en) * 2017-04-26 2019-02-19 石家庄蒎格医药科技有限公司 A kind of 9-hydroxy-risperidone polyethylene glycol conjugation prodrug and preparation
IL270169B2 (en) 2017-04-27 2024-08-01 Univ Johns Hopkins Dendrimer compositions for use in angiography
US11344627B2 (en) * 2017-06-27 2022-05-31 Wisconsin Alumni Research Foundation Dendrimer-exosome hybrid nanoparticles as a delivery platform
WO2019094952A1 (en) 2017-11-10 2019-05-16 The Johns Hopkins University Dendrimer delivery system and methods of use thereof
JP2021527198A (en) 2018-06-07 2021-10-11 センサーズ インコーポレイテッド Particle concentration analysis system and method
CA3163892A1 (en) 2019-12-04 2021-06-10 Ashvattha Therapeutics, Inc. Dendrimer compositions and methods for drug delivery to the eye
EP3928766A1 (en) * 2020-06-26 2021-12-29 Usso Barnas Pharmaceutical composition and use thereof
JP2024504512A (en) 2020-12-21 2024-01-31 コーネル・ユニバーシティー Peptide-linked drug delivery system
WO2024044756A1 (en) * 2022-08-26 2024-02-29 The Johns Hopkins University Dendrimer compositions for targeted delivery of psychedelic therapeutics

Family Cites Families (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH625702A5 (en) 1977-01-18 1981-10-15 Delalande Sa
EP0099758B1 (en) 1982-07-21 1988-10-12 University of Strathclyde Composite wound dressing
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4631337A (en) 1983-01-07 1986-12-23 The Dow Chemical Company Hydrolytically-stable dense star polyamine
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4737550A (en) 1983-01-07 1988-04-12 The Dow Chemical Company Bridged dense star polymers
US4939240A (en) 1983-03-04 1990-07-03 Health Research, Inc. Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
NL8401912A (en) 1984-06-15 1986-01-02 Tno BIODEGRADABLE POLYMER SUBSTRATES LOADED WITH ACTIVE SUBSTANCE, SUITABLE FOR THE CONTROLLED DELIVERY OF THE ACTIVE SUBSTANCE BY MEMBRANE.
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
US4708930A (en) 1984-11-09 1987-11-24 Coulter Corporation Monoclonal antibody to a human carcinoma tumor associated antigen
US4918164A (en) 1987-09-10 1990-04-17 Oncogen Tumor immunotherapy using anti-idiotypic antibodies
US4743543A (en) 1985-09-09 1988-05-10 Coulter Corporation Method for enhancing and/or accelerating immunoassay detection of human carcinoma tumor associated antigen in a pathology sample
US4871779A (en) 1985-12-23 1989-10-03 The Dow Chemical Company Ion exchange/chelation resins containing dense star polymers having ion exchange or chelate capabilities
US4694064A (en) 1986-02-28 1987-09-15 The Dow Chemical Company Rod-shaped dendrimer
US4713975A (en) 1986-05-30 1987-12-22 The Dow Chemical Company Dense star polymers for calibrating/characterizing sub-micron apertures
US4827945A (en) 1986-07-03 1989-05-09 Advanced Magnetics, Incorporated Biologically degradable superparamagnetic materials for use in clinical applications
JPS6319561A (en) 1986-07-11 1988-01-27 Kyowa Hakko Kogyo Co Ltd Anti-human lung cancer monoclonal antibody
DE3786000T3 (en) 1986-08-18 1997-08-21 Dow Chemical Co Conjugate dense stars.
US5527524A (en) 1986-08-18 1996-06-18 The Dow Chemical Company Dense star polymer conjugates
WO1995024221A1 (en) 1986-08-18 1995-09-14 The Dow Chemical Company Bioactive and/or targeted dendrimer conjugates
US5338532A (en) 1986-08-18 1994-08-16 The Dow Chemical Company Starburst conjugates
US5560929A (en) 1986-08-18 1996-10-01 The Dow Chemical Company Structured copolymers and their use as absorbents, gels and carriers of metal ions
US6312679B1 (en) * 1986-08-18 2001-11-06 The Dow Chemical Company Dense star polymer conjugates as dyes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4921790A (en) 1987-04-24 1990-05-01 Research Corporation Tumor specific assay for CA125 ovarian cancer antigen
DE3856108T2 (en) 1987-07-15 1998-07-09 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. SECOND GENERATION MONOCLONAL ANTIBODIES WITH BINDING SPECIFICITY FOR TAG-72 AND HUMAN CARCINOMAS AND METHODS FOR THEIR USE
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5053489A (en) 1988-01-29 1991-10-01 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US4857599A (en) 1988-02-08 1989-08-15 The Dow Chemical Company Modified dense star polymers
US4914021A (en) 1988-03-04 1990-04-03 New England Deaconess Hospital Corporation Carcinoma orosomucoid-related antigen, a monoclonal antibody thereto, and their uses
US4921789A (en) 1988-04-20 1990-05-01 New England Deaconess Hospital Corporation Marker for colorectal carcinoma and methods of detecting the same
JPH0734015B2 (en) 1988-04-25 1995-04-12 和光純薬工業株式会社 New method for measuring trace components
SE463851B (en) 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
US5041516A (en) 1989-06-21 1991-08-20 Cornell Research Foundation, Inc. Dendritic molecules and method of production
US5318529A (en) 1989-09-06 1994-06-07 Boston Scientific Corporation Angioplasty balloon catheter and adaptor
US5110911A (en) 1989-11-02 1992-05-05 Biomira, Inc. Human tumor-associated thomsen-friedenreich antigen
US5843089A (en) 1990-12-28 1998-12-01 Boston Scientific Corporation Stent lining
US5674192A (en) 1990-12-28 1997-10-07 Boston Scientific Corporation Drug delivery
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5874218A (en) 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US5773527A (en) 1990-08-27 1998-06-30 Dendritech, Inc. Non-crosslinked, polybranched polymers
US5631329A (en) 1990-08-27 1997-05-20 Dendritech, Inc. Process for producing hyper-comb-branched polymers
US5876445A (en) 1991-10-09 1999-03-02 Boston Scientific Corporation Medical stents for body lumens exhibiting peristaltic motion
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6113946A (en) 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5354308A (en) 1992-05-01 1994-10-11 Beth Israel Hospital Association Metal wire stent
DE69327229T2 (en) 1992-12-11 2000-03-30 The Dow Chemical Co., Midland Multivalent single chain antibodies
US5387617A (en) 1993-01-22 1995-02-07 The Dow Chemical Company Small cell foams and blends and a process for their preparation
WO1994018562A1 (en) 1993-02-05 1994-08-18 Epigen, Inc. Human carcinoma antigen (hca), hca antibodies, hca immunoassays, methods of imaging and therapy
AU6267794A (en) 1993-02-24 1994-09-14 Dade International Inc. Immobilization of specific binding assay reagents
US5898005A (en) 1993-02-24 1999-04-27 Dade Behring Inc. Rapid detection of analytes with receptors immobilized on soluble submicron particles
US5913894A (en) 1994-12-05 1999-06-22 Meadox Medicals, Inc. Solid woven tubular prosthesis
DE69429670T2 (en) 1993-08-23 2002-08-22 Boston Scientific Corp., Natick IMPROVED BALLOON CATHETER
US5609627A (en) 1994-02-09 1997-03-11 Boston Scientific Technology, Inc. Method for delivering a bifurcated endoluminal prosthesis
US5733303A (en) 1994-03-17 1998-03-31 Medinol Ltd. Flexible expandable stent
GB9407812D0 (en) 1994-04-20 1994-06-15 Nycomed Salutar Inc Compounds
EP0858298A4 (en) 1994-04-29 1999-04-07 Boston Scient Corp Medical prosthetic stent and method of manufacture
US5857998A (en) 1994-06-30 1999-01-12 Boston Scientific Corporation Stent and therapeutic delivery system
US5620417A (en) 1994-07-07 1997-04-15 Cardiovascular Imaging Systems Incorporated Rapid exchange delivery catheter
US5755722A (en) 1994-12-22 1998-05-26 Boston Scientific Corporation Stent placement device with medication dispenser and method
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
IT1275433B (en) 1995-05-19 1997-08-07 Smithkline Beecham Farma DIARYLDIAMINE DERIVATIVES
EP0831753B1 (en) 1995-06-01 2005-12-28 Meadox Medicals, Inc. Implantable intraluminal prosthesis
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6083708A (en) 1995-08-11 2000-07-04 Dade Behring Inc. Polypeptide: dendrimer complexes
US5795582A (en) 1996-02-07 1998-08-18 Novavax, Inc. Adjuvant properties of poly (amidoamine) dendrimers
US5855881A (en) 1996-02-22 1999-01-05 Loike; John D. Mammalian alcohol dehydrogenase and aldehyde dehydrogenase production in plants
US6054444A (en) 1997-04-24 2000-04-25 Guilford Pharmaceuticals Inc. Phosphonic acid derivatives
US5792105A (en) 1996-09-11 1998-08-11 Boston Scientific Corporation Multichannel balloon catheter for delivering fluid
US5868719A (en) 1997-01-15 1999-02-09 Boston Scientific Corporation Drug delivery balloon catheter device
US5933145A (en) 1997-04-17 1999-08-03 Microsoft Corporation Method and system for visually indicating a selection query
US6585956B2 (en) 1997-07-07 2003-07-01 The Dow Chemical Company Dendritic-platinate drug delivery system
US6143558A (en) 1997-07-08 2000-11-07 The Regents Of The University Of Michigan Optical fiberless sensors for analyzing cellular analytes
US5902863A (en) 1997-07-21 1999-05-11 Dow Corning Corporation Dendrimer-based networks containing lyophilic organosilicon and hydrophilic polyamidoamine nanoscopic domains
US5866561A (en) 1997-08-21 1999-02-02 Scimed Life Systems, Inc. Local delivery of estrogen for angiogenesis
GB9718129D0 (en) 1997-08-27 1997-10-29 Isis Innovation Branched structures
US7368512B2 (en) * 1997-09-23 2008-05-06 University Of South Florida Detection and functionalization of dendrimers
US5908413A (en) 1997-10-03 1999-06-01 Scimed Life Systems, Inc. Radiopaque catheter and method of manufacture thereof
US6267987B1 (en) 1997-12-12 2001-07-31 Samyang Corporation Positively charged poly[alpha-(omega-aminoalkyl) glycolic acid] for the delivery of a bioactive agent via tissue and cellular uptake
SI1685839T1 (en) * 1997-12-22 2013-08-30 Euro-Celtique S.A. Pharmaceutical oral dosage form comprising a combination of an opioid agonist and opioid antagonist
WO1999058656A2 (en) 1998-05-13 1999-11-18 The Regents Of The University Of Michigan Sustained dna delivery from structural matrices
GB9811403D0 (en) 1998-05-27 1998-07-22 Isis Innovation Polynucleotide multimers and their use in hybridisation assays
US7572459B2 (en) * 1998-09-14 2009-08-11 Starpharma Pty Ltd. Anionic or cationic dendrimer antimicrobial or antiparasitic compositions
US7081495B1 (en) 1998-09-23 2006-07-25 School Of Pharmacy, University Of London Cationic compounds and their use as macro molecular carriers
US6485718B1 (en) 1999-04-13 2002-11-26 Pharmacia Corporation Site specific ligation of proteins to synthetic particles
JP2003503591A (en) 1999-06-29 2003-01-28 ダコ エー エス Detection using dendrimers carrying labels and probes
US20020042536A1 (en) 1999-10-08 2002-04-11 Prasad S. Raje Preparation of amino-protected lysine derivatives
MXPA02007956A (en) * 2000-02-18 2004-09-10 Gencell Sa Method for preparing functionalised polyalkylenimines, composition containing same and uses thereof.
EP1259808A2 (en) 2000-03-10 2002-11-27 Washington University Method for labeling individual cells
US6471968B1 (en) 2000-05-12 2002-10-29 Regents Of The University Of Michigan Multifunctional nanodevice platform
US20040120979A1 (en) 2000-06-02 2004-06-24 Roessler Blake J. Delivery systems comprising biocompatible and bioerodable membranes
US7097856B2 (en) * 2000-09-29 2006-08-29 The Regents Of The University Of California Dendrimeric support or carrier macromolecule
JP2002265495A (en) 2001-03-09 2002-09-18 Taiho Yakuhin Kogyo Kk Basic new dendrimer or pharmaceutically acceptable salt thereof, and neovascularization inhibitor
AU2002327180A1 (en) 2001-06-04 2003-01-21 The General Hospital Corporation Detection and therapy of vulnerable plaque with photodynamic compounds
TWI240632B (en) 2001-07-30 2005-10-01 Epix Medical Inc Purified peptides for peptide-based multimeric targeted contrast agents
US20040109842A1 (en) * 2001-10-26 2004-06-10 Baker James R. Ballistic transfection with dendrimers
US7261875B2 (en) 2001-12-21 2007-08-28 Board Of Regents, The University Of Texas System Dendritic poly (amino acid) carriers and methods of use
US20030180250A1 (en) 2002-03-22 2003-09-25 Council Of Scientific And Industrial Research Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents
GB0209022D0 (en) * 2002-04-19 2002-05-29 Imp College Innovations Ltd Compounds
US7459145B2 (en) 2002-10-25 2008-12-02 Georgia Tech Research Corporation Multifunctional magnetic nanoparticle probes for intracellular molecular imaging and monitoring
EP1601669B1 (en) * 2003-03-07 2008-12-24 Schering Corporation Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
US7846201B2 (en) 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US7745229B2 (en) * 2004-04-16 2010-06-29 University Of South Carolina Chemoselective fluorgenic molecular linkers and methods for their preparation and use
US7985424B2 (en) * 2004-04-20 2011-07-26 Dendritic Nanotechnologies Inc. Dendritic polymers with enhanced amplification and interior functionality
CN101006119A (en) * 2004-06-30 2007-07-25 斯克里普斯研究学院 Click chemistry route to triazole dendrimers
DE102004039102A1 (en) * 2004-08-11 2006-02-23 Basf Ag Process for the preparation of highly branched polyesteramides
US20090104119A1 (en) * 2004-08-25 2009-04-23 Majoros Istvan J Dendrimer Based Compositions And Methods Of Using The Same
US20080171067A1 (en) 2007-01-17 2008-07-17 Immunomedics, Inc. Polymeric Carriers of Therapeutic Agents and Recognition Moieties for Antibody-Based Targeting of Disease Sites
DE602006019709D1 (en) * 2005-05-02 2011-03-03 Anp Technologies Inc
EP1733742A1 (en) 2005-06-17 2006-12-20 Universiteit Utrecht Holding B.V. Dendrimers multivalently substituted with active groups
US20070020620A1 (en) * 2005-07-14 2007-01-25 Finn M G Compositions and methods for coupling a plurality of compounds to a scaffold
WO2007011967A2 (en) 2005-07-18 2007-01-25 The Scripps Research Institute Method of using click chemistry to functionalize dendrimers
JP2009506136A (en) 2005-07-18 2009-02-12 ザ スクリプス リサーチ インスティテュート Preparation of amphiphilic dendrimers
US20100136614A1 (en) * 2005-10-18 2010-06-03 Dan Luo Dendrimer-like modular delivery vector
US20070041934A1 (en) * 2005-08-12 2007-02-22 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
US20090208580A1 (en) * 2005-09-19 2009-08-20 Regents Of The University Of Michigan Functionalized dendrimer-encapsulated and dendrimer-stabilized nanoparticles
JPWO2007034750A1 (en) 2005-09-22 2009-03-26 株式会社資生堂 Wrinkle improver
CU23556A1 (en) * 2005-11-30 2010-07-20 Ct Ingenieria Genetica Biotech POLYMER STRUCTURE SIMILAR TO DENDRÍMERO FOR THE OBTAINING OF CONJUGATES OF PHARMACEUTICAL INTEREST
WO2007080114A2 (en) 2006-01-11 2007-07-19 Biotech Igg Ab Macromolecule conjugate
US20090053139A1 (en) * 2006-07-12 2009-02-26 Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
AU2008275501A1 (en) * 2007-04-19 2009-01-15 The Regents Of The University Of Michigan Dendrimer based compositions and methods of using the same
WO2009006046A1 (en) * 2007-06-29 2009-01-08 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Dendrimer conjugates of agonists and antagonists of the gpcr superfamily
US8252834B2 (en) * 2008-03-12 2012-08-28 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010039861A2 (en) 2008-09-30 2010-04-08 The Regents Of The University Of Michigan Dendrimer conjugates
JP5709266B2 (en) 2008-12-08 2015-04-30 ソリジェニックス、インコーポレイテッド Topically active steroids for radiation and chemotherapy injury
WO2010075423A2 (en) * 2008-12-23 2010-07-01 The Regents Of The University Of Michigan Dendrimer based modular platforms
US8853151B2 (en) 2009-06-30 2014-10-07 The Regents Of The University Of Michigan Pro-drug complexes and related methods of use
US20120232225A1 (en) 2009-08-26 2012-09-13 The Regents Of The University Of Michigan Synthesis and isolation of dendrimer systems
US8945508B2 (en) 2009-10-13 2015-02-03 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011053618A2 (en) 2009-10-30 2011-05-05 The Regents Of The University Of Michigan Hydroxyl-terminated dendrimers
WO2011072290A2 (en) 2009-12-11 2011-06-16 The Regents Of The University Of Michigan Targeted dendrimer-drug conjugates

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAMERON C. LEE ET AL.: "Designing dendrimers for biological applications", NATURE BIOTECHNOLOGY, vol. 23, no. 12, December 2005 (2005-12-01), pages 1517 - 1526 *
FRANCISCUS M. H. DE GROOT ET AL.: ""'Cascade-Release Dendrimers" Liberate All End Groups upon a Single Triggering Event in the Dendritic Core", ANGEW. CHEM. INT. ED., vol. 42, 2003, pages 4490 - 4494 *

Also Published As

Publication number Publication date
WO2010039861A2 (en) 2010-04-08
US8889635B2 (en) 2014-11-18
US20140128327A1 (en) 2014-05-08
US8980907B2 (en) 2015-03-17
US20100160299A1 (en) 2010-06-24

Similar Documents

Publication Publication Date Title
WO2010039861A3 (en) Dendrimer conjugates
WO2009151687A3 (en) Dendrimer conjugates
WO2008008483A3 (en) Dendrimer based compositions and methods of using the same
WO2011011384A3 (en) Synthesis of dendrimer conjugates
WO2009009203A3 (en) Dendrimer based compositions and methods of using the same
WO2011059609A3 (en) Dendrimer compositions and methods of synthesis
WO2011028334A3 (en) Synthesis and isolation of dendrimer systems
WO2010075423A3 (en) Dendrimer based modular platforms
WO2011045415A3 (en) Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
WO2011053901A3 (en) Magnetic nanostructures as theranostic agents
EP4279140A3 (en) Human antibodies against tissue factor
WO2006113666A3 (en) Amphiphilic polymers and methods of use thereof
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2011002852A3 (en) Pro-drug complexes and related methods of use
EP1988910A4 (en) Acryloyloxyethylphosphorylcholine containing polymer conjugates and their preparation
WO2010057112A3 (en) Genetic variants underlying human cognition and methods of use thereof as diagnostic and therapeutic targets
WO2007018431A3 (en) Triazole-containing releasable linkers and conjugates comprising the same
WO2006099169A3 (en) Novel liposome compositions
WO2007105027A8 (en) Anticancer drugs conjugated to antibody via an enzyme cleavable linker
WO2008091555A3 (en) Nuclear receptor binding agents
WO2011008696A3 (en) Diagnostic methods and compositions for treatment of cancer
WO2008103920A3 (en) Targeted protein cages
WO2010046900A3 (en) Rgd-containing peptidomimetics and uses thereof
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
WO2009123934A3 (en) Branched multifunctional nanoparticle conjugates and their use

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09818457

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09818457

Country of ref document: EP

Kind code of ref document: A2